bluuebunny/crossref_metadata_2025_split huggingface dataset:
CHEMOTAXIS OF POLYMORPHONUCLEAR LEUKOCYTES BY VASCULAR PERMEABILITY FACTOR FROM BOVINE PLATELETS
Authors: Hoshikawa N , Niino H , Imura J , Ashihara Y , Shirasawa K 
Published: August 2018

Bovine platelet a-granule acid extract (BPAE) contains vascular permeability factor (VPF) as human platelets. VPF plays as a mediator depending on polymorphonuclear (PMN) leukocytes and possesses a potent cell growth activity in cultured fibroblasts. This study was carried out to examine the chemotactic activity of VPF for PMN leukocytes of rabbits. For the study of chemotaxis, the PMN leukocytes were collected from the ascites after production by an injection of 0.1% oyster glycogen in 0.85% NaCl solution into the peritoneal cavity of rabbits. They were suspended in the Gey's balanced salt solution with supplementation of 2% human albumin. Partial purification of BPAE was performed by gel filteration using Sephadex G-50 so as to exclude the influence of PF-4 and 8-TG. BPAE, as the attractant solution, was prepared at the several concentration in the Gey's solution. Human serum activated with zymosan was used as the positive control. Effects of protamine sulfate, a competitive inhibitor of platelet-derived growth factor (PDGF), on the chemotactic activity of VPF were also studied. Chemotaxis of the PMN leukocytes was measured in the modified Boyden chamber with a 3jJm-pore filter. Five high power (x400) grids were counted per filter and cell migration was corrected by subtraction of blanks in which the lower compartment contained medium only. The most striking chemotactic response was obtained when BPAE was used at the concentration of 0.1μg/ml. However, the response was reduced at the concentration of more than 1μg/ml. The activity of BPAE (0.1μg/ml) was about 60% of the positive control level. The migration was reduced to 18% of the positive control by protamine sulfate (3μg/ml) at that concentration of BPAEIt is concluded that VPF induces chemotaxis to PMN leukocytes at the concentration lesser than that enhancing the vascular permeability response. Furthermore, protamine sulfate inhibits the VPF-induced migration of PMN leukocytes. Those findings may indicate that VPF acts as PDGF in function. Therefore, it is likely that the factor attracts PMN leukocytes and promotes cell growth in the inflamed region
HEPARIN ANTICOAGULATION AND ITS EFFECT ON ARTERIAL THROMBUS FORMATION IN THE RABBIT
Authors: Shand R A , Butler K D , Davies J A 
Published: August 2018

Injury to the rabbit carotid was induced by clamping the vessel for 5 minutes. Deposition of radiolabelled fibrinogen (F) or platelets (PL) on the injured carotid was monitored continuously, for 45 minutes, using an iodide crystal scintillation detector positioned over the vessel linked to an automated isotope monitoring system (AIMS 8000). The results were expressed as the maximal increase or as the area under the curve (AUC) for the recording period.Following injury there was a simultaneous increase in both F associated and PL associated radioactivity of 29% (median value, range 10.9 - 4.37) and 11% (range 7.45 - 24.7) respectively above control values. The response as measured by the AUC was 47,000 ± 8,550 and 15,000 ± 5,600 respectively.Heparin (250 IU/kg, i.v. bolus) did not influence F deposition following injury and only produced a transient prolongation of the prothrombin time. If the same bolus dose of heparin was followed by an infusion of 670 IU/kg/hr there was a significant reduction of both the maximal increase and the AUC of F deposition (45% and 55% respectively). There was also a sustained (2-3 fold) prolongation of the prothrombin time. Heparin (500 IU/kg i.v. plus infusion of 670 IU/kg/hr) significantly impaired both the maximal increase and AUC of F deposition (by 33% and 69% respectively) and PL deposition (79% and 100% respectively). No significant changes in either albumin or erythrocyte associated radioactivity in the injured carotid artery of control or treated rabbits were found.This data demonstrates that anticoagulation, using heparin, inhibits fibrin(ogen) and platelet deposition, but not permeability changes, in the injured rabbit carotid artery. This highlights the interdependence in arterial thrombus formation of both the coagulation system and platelets.
PLATELET ASSOCIATED IMMUNOGLOBULINS IN PATIENTS WITH NON - HODGKIN'S LYMPHOMAS
Authors: Lawandowski K , Zawilska K , Komarnicki M , Zozulińsks M 
Published: August 2018

Levels of platelet associated IgG and IgM were studied in 42 patients with non-Hodgkin'a lymphomas / NHL / using rocket inaunoelectrophore8i8 in agarose gel . Twenty percent of patients with NHL had elevated PAIgG and fifty percent had elevated PAIgM levels.Both PAIgG and PAIgM ware strongly correlated with the extend of disease . When patients with NHL and elevated PAIgM levels were treated by chemotherapy , PAIgM levels normalized aa tumor load diminished . No similar correlation axsited between response to the therapy and levels of PAIgG in patients with NHL. These data suggest that PAIgM may be useful as a marker for disease activity and may be an early indicator of relapse when measured periodicaly in patients who have completed therapy.
CHARACTERISATION OF PLATELET AGGREGATING MATERIAL EXTRACTED FROM HUMAN LUNG ADENOCARCINOMA CELL LINE WHICH METASTASIZED IN NUDE MICE S,C, IMPLANTATION
Authors: Inufusa H , Sagara N , Nakano K , Yasutomi M 
Published: August 2018

It has been reported in animal experimental system that Platelet Aggregating Material (PAM) of cancer cell play important role in cancer metastasis. Many human cancer cell lines has been also studied the platelet aggregation activity of PAM. But correlation between the platelet aggregation activity and metastatic potential of human cancer cells were usually unkncwn. We established a human lung adenocarcinoma cell line KUM-LK-2 which produce spontaneous lung metastasis when cells implanted into subcutaneous of nude mice. PAM was extracted from KUM-LK-2 cells following the method of D.Mbhanty and P.Hilgard. Platelet aggregation study of PAM was performed by human Heparinized platelet rich plasma useing NIKO Hematracer PACT2D. Character of PAM were examined by physical and chemical treatment. KUM-LK-2 PAM shew 80% of platelet aggregation in maximum after 150 sec lag time, and aggregation was not found by Citrated PRP.It is concluded that PAM is high moleculer protein and contain Phospholipid and aggregation activity is concerning with ATP composition of platelet. PAM dose not contain Fibrinogen and Sialic acid, and not concern with Throrriboxan composition. This study is first case of platelet aggregation activity of PAM extracted human canoer cells which contain metastatic potential.
PLATELET ACTIVATION BY HUMAN CANCER CELLS GROWN “IN VITRO” OR DISSOCIATED FROM TUMOUR TISSUES
Authors: Grignani G , Pacchiarini L , Zucchella M , Dezza L , Rizzo S C 
Published: August 2018

The mechanisms of platelet activation by human tumour cells grown “in vitro” or freshly dissociated from tumour tissues have been investigated.MoCCL human T-lymphoblastic cells cultured “in vitro” induced platelet aggregation through the production of ADP, as evidenced by inhibition of the effect by apyrase. The maximum of ADP production by tumour cells was reached after 1 hour and was 225 p moles/106 cells.On the contrary, platelet aggregation induced by 5637 human bladder carcinoma cells was not inhibited by apyrase, but was abolished by hirudin, indicating the important role of thrombin in this effect.Tumour cells dissociated from 3 breast carcinomas showed a very high platelet aggregating activity, which was not inhibited by hirudin or apyrase, but was abolished by iodoacetic acid, suggesting a role for a cystein-protease in platelet activation.These results confirm that platelets can be activated by tumour cells through different mechanisms; they also suggest that the methods employed to obtain the tumour cells can influence the results, probably because of the different cell populations which are present in the dissociated tumour tissues.Informations obtained with freshly dissociated cells are interesting, because this method has been used seldom so far and because it provides a more physiological approach to the study of the interactions of tumours and platelets.
ADHESION OF TUMOR CELLS TO EXTRACELLULAR MATRIX IS MEDIATED BY FIBRONECTIN
Authors: Almirall L , Aznar-Salatti J , Calopa I , Ordinas A , Bastida E 
Published: August 2018

Tumor cell (TC) vessel wall adhesion is thougth to occur at specific sites of exposed extracellular matrix (ECM).To determine the role of fibronectin (FN) in TC/ECM adhesion,we measured; 1)TC adhesion to intact cultured endothelial cell monolayers (EC) or their ECMs,with or without incubation with a polyclonal antibody (Ab) to human FN, or a monoclonal antibody (Mab) to the cell binding site of FN (3E3);2)TC adhesion to EC or their exposed ECMs incubated with specific peptides against bacteria adhesion sites (I 133-79) or the peptide GRGDSP contained in the cell binding sites of several adhesive proteins.TC adhesion was measured as number of 111In-labeled A-549 adenocarcinoma cellsxlO /disc. ECMs were exposed by removing the ECs with N2 flow or EGTA treatment.There was 5.5±1x10 A-549/ EC covered disc (Table). Treatment of ECs with the Abs or peptides had no effect on TC adhesion.TC adhesion to the two ECM preparation were 42 ± 12 and 55±10 respectively.(Table).Blockage of the FN adhesive site by either Ab inhibited TC adhesion (p < 0.01). In contrast,blockage of the bacteria-adhesion site or incubation with GRGDSP had not significant effects in TC adhesion. The table shows the results (mearv±SEM (* p < 0.01).We conclude that TC adhesion to ECM but not to ECs,is dependent upon FN.
ENOXAPARINE (LOVENOXR), DURING RENAL DIALYSIS, IN 46 PATIENTS WITH CHRONIC RENAL FAILURE (CRF) AND WITH HIGH RISK OF BLEEDING (HRB)
Authors: DECHELETTE E , POUZOL P , JURKOVITZ C , POLACK B 
Published: August 2018

Standard heparin, usually used as an anticoagulant during hemodialysis, may be dangerous in patients with HRB. Low-molecular-weight-heparin (LMWH) fragments have been shown to induce less bleeding than standard heparin. We assessed the ability of Enoxaparine, a LMWH, to prevent clotting during hemodialysis, in such patients.46 patients with CRF, requiring regular maintenance hemodialysis were included. 136 episodes of HRB occurred in these 46 patients : renal transplantation (17) , deep vessel catheterization (18) , biopsy (11), surgical.operation other than renal transplantation (46), obvious bleeding or HRB (44). 493 hemodialysis were performed using a single dose of Enoxaparine, as a bolus, 0.5 mg/kg for a double pass system, 0.75 mg/kg for a single pass system. Blood flow rate was maximum (350 ml/mn) in case of arterio-venous fistulas, and varied between 200 and 250 ml/mn in case of superior veina cava catheters. Air-blood exchange areas were maintained as small as possible. Bubble traps were examined every half an hour. Hemodialysis lasted 4 or 5 hours.Extensive clotting within the extracorporeal circulation occurred only 3 times (0.6 %) ; (in 2 of the 102 hemodialysis performed with a single pass system and in 1 of the 391 hemodialysis performed with a double pass system). Efficiency of hemodialysis was always very good ; one patient had a genital hemorrhage requiring red cell transfusion. No other bleeding complication due to Enoxaparine was detected. 7 surgical operations and 3 renal biopsies were performed just after a hemodialysis without any problem.This study shows that hemodialysis can be performed with Enoxaparine, 0.5 - 0.75 mg/kg, as a bolus in patients with HRB. It is efficient in preventing clotting, does not increase the risk of bleeding and ensures a very good quality of extrarenal filtration.Enoxaparine (LOVENOXR) - PHARMUKA S.F.
THE ANTICOAGULANT EFFECT OF ENOXAPARINE (LOVENOXR) DURING HEMODIALYSIS
Authors: POUZOL P , DECHELETTE E , JURKOVITZ C 
Published: August 2018

Enoxaparine is a low-molecular-weight-heparin obtained by partial and controlled depolymerization of a heparin of mucosal hog origin. We aimed at the evaluation of the efficacity of a unique injection of Enoxaparine in the prevention of blood clotting in the dialysis circuit in 42 patients with chronic renal failure. Three doses were tested : 0.75, 1.00, 1.25 mg/kg body weight in an open study with a crossing over of the three doses which were randomized according to a latin square design with a one week interval between each dose. None of the dialysis were impaired with clotting of the circuit and never an additional administration of anticoagulant was required in order to achieve the dialysis. Antithrombotic effectiveness was assessed by the quality of arterial and venous lines restitution and by visual inspection of the bubbles trap. No hemorrhagic event occurred. APTT didn’t show residual hypocoagulability at the end of dialysis. Anti-Xa and anti-IIa activities 4 hours after administration were :Anti-Xa and anti-IIa activities exhibited a linear dose level
relationship. Efficiency and tolerance were excellent for the three doses.Enoxaparine (LOVENOXR) PHARMUKA S.F.
EFFICACY AND SAFETY OF A LOW MOLECULAR WEIGHT HEPARIN (L M W H KABI 2165) IN PROPHYLAXIS OF POSTOPERATIVE DEEP VEIN THROMBOSIS (D.V.T.) AFTER ONCOLOGICAL SURGERY
Authors: Graunebaum L , Fricker J-P , Wiesel M-L , Vergnes Y , Cazenave J-P , Barbier P , Kher A 
Published: August 2018

The effect of a LMWH - Kabi 2165 on thrombo-embolism prophylaxis was studied in a prospective, randomized trial of 74 patients scheduled for surgery due to malignant diseases. 38 patients received 2 500 anti-Xa units S.C. 2 hours before operation, then 12 hours after and then 5 000 anti-Xa units once a day for 10 days. 36 patients were given calcium heparin 5 000 i.u S.C. 2 hours before operation and then three time a day for 10 days. 125I-Fibrinogen uptake test was used in all patients to detect D.V.T. Positive scan was controlled by phlebography. In the Kabi 2165 group, 2 patients had positive scan not confirmed by phlebography No pulmonary embolism was reported. In the calcium heparin group, 2 patients developed non fatal pulmonary embolism. The fibrinogen test was negative in all the patients. Intra and postoperative blood loss, transfusion requirements, wound hematomas and infectious complications did not differ significantly between the two groups. The mean values of hematocrit and hemoglobin preoperatively and post operatively (day 1, and 10) were similar for the two groups :It is concluded that a single daily injection of 5 000 anti-Xa units of Kabi 2165 may provide a prophylaxis against postoperative venous thromboembolism as effective and as safe as 3 daily injections of 5 000 i.u. of calcium heparin in oncological surgery.
COMPARATIVE CLINICAL PHARMACOLOGY OF LOW MOLECULAR WEIGHT HEPARINS IN MAN
Authors: Ordu Y , Augustin J , Hodenberg E V , Bode V , Harenberg J 
Published: August 2018

Low molecular weight (LMW) heparins are obtained by diffent chemical procedures from conventional pig intestinal mucosa heparin. The LMW heparins differ in their molecular weight distribution and physicochemical properties. Therefore, we report of comparative studies on the anticoagulant and lipolytic effects of low molecular weight heparins in man.The following LMW heparins were used: BM 21-23 (Braun, Melsungen, FRG), CY 216 (Choay Laboratories, Paris, France), Heparin NM (Sandoz, Niimberg, FRG), Kabi 2165 (Kabi Vitrum AB, Stockholm, Sweden), RD Heparin (Hepar Industries, Franklin, US A), normal heparin (Braun). All heparins were administered intravenously and subcutaneously to six volunteers each.The data show considerable differences in the anticoagulant and lipolytic effects between the different low molecular weight heparins. From the area under the activity time curves (AUC) of the clotting assays for factor Xa (heptest), aPTT and thrombin clotting time the aXa/aPTT ratio ex vivo and aXa/alla ratio ex vivo were determined (table, average values)It can be seen that there are clear differences in the ex vivo ratios of the LMW heparins. There is a good correlation between the average molecular weight of the LMW heparins and the aXa/aPTT ratio after s.c. administration and of the aXa/alla ratio ex vivo after s.c. administration. Therefore, LMW heparins differ significantly in their clinical pharmacological properties.
TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS (DVT) OF THE LOWER LIMBS BY CY 216* (LMWH) VERSUS UNFRACTIONATED HEPARIN (UFH)
Authors: Duroux P 
Published: August 2018

Preliminary clinical data showed CY 216 could be effective in the treatment of established DVT. Thus, we undertook an European collaborative controlled randomised study to assess the efficacy and tolerance of this new antithrombotic agent.140 patients presenting a proximal DVT of less than 5 days confirmed by phlebogram, are randomly allocated into 2 groups, one treated by UFH with constant pump infusion, at doses daily adapted to laboratory tests, the other one by CY 216 at a mean daily dosage of 450 aXa IC u** calculated at onset of treatment on body weight, administered daily by 2 sub-cutaneous injections during 10 days, without dosage adaptation whatever the lab. tests results.The efficacy is assessed on comparison on both phlebograms (Harder and Arnessen Indexes) and lung Scans performed before inclusion and after end of treatment. In addition, tolerance is appreciated on the incidence of bleeding complications. Furthermore, incidence of clinical DVT recurrence is assessed at 12th week.The present study is still in progress, 130 patients are included ; the preliminary results tend to show that CY 216 at fixed doses, body weight adapted, is an effective and safe treatment of proximal deep vein thrombosis.* CY 216 : FraxiparineR Choay** Axa IC u : anti-factor Xa Institut Choay unit.
EFFECTS OF ORG 10172, A NOVEL LMW HEPARINOID ON PRIMARY HAEMOSTASIS IN RATS AND HUMANS. A MORPHOLOGICAL STUDY
Authors: Wester J , Van Mensvoort F W J , Meuleman D G , ten Cate H , Henny C P , ten Cate J W 
Published: August 2018

Org 10172 is a novel low molecular weight heparinoid isolated from animal mucosa with a higher anti-thrombotic/bleeding risk ratio than standard heparin. The effects of Org 10172 and heparin on primary haemostasis in rats and humans have been studied by light and electron microscopy (LM&EM).In rat ears bleeding wounds were inflicted. The wound areas were excised 5, 15 or 30 min. after bleeding induction, and processed for LM and EM. Org 10172 and heparin have been administered in doses of 300 or 600 anti-Xa U/kg i.v., 5 or 1 min. prior to bleeding induction. Bleeding wounds of drug treated animals have been compared with those of placebo animals. Heparin inhibited degranulation as well as fibrin deposition and groups of not aggregated, sometimes even discoidal platelets could be found after heparin treatment. Org 10172 inhibited degranulation to some extent but less than heparin and Org 10172 hardly inhibited fibrin deposition.In six human volunteers SimplateR bleeding time wounds were excised by punch biopsy, 20 min. after bleeding induction and processed for LM and EM. Org 10172 was administered as single bolus injection of either 3200 or 6400 anti-Xa U i.v., 10 min. prior to bleeding induction. Heparin was given in a dosis of 10.000 anti-Xa U i.v. All biopsies from post-drug bleeding time wounds were compared with biopsies taken from pre-drug bleeding time wounds in the same volunteer. As in the rat studies, heparin inhibited degranulation and fibrin deposition whereas after Org 10172 treatment these effects were hardly detectable. In general the effects of both drugs on haemostasis in the human volunteer study were less distinct than in the rat study. This may be attributed to the lower dose levels used.In conclusion, primary haemostasis after Org 10172 treatment is somewhat retarded, but essentially normal, whereas haemostasis after heparin treatment is more severely disturbed.
CLINICAL PHARMACOLOGY OF DERMATAN SULFATE: EFFECT ON HAEMOSTATIC PARAMETERS
Authors: Piovella F , Pogliani E M , Custodi P , Antonioli R , Gianese F 
Published: August 2018

In experimental studies dermatan sulfate (DS) has been characte riZed as an effective antithrombotic agent. This property is not associated with modifications of standard coagulation tests or in creased blood loss “in vivo”.(*)In view of a possible clinical use of DS, we performed a prelirmi nary study on 10 consenting hospitalized patients without eviden ce of haemostatic abnormalities.Each subject was given i.m. single increasing doses (50, 100, 200 mg) of DS (MF 701, Mediolanum Farmaceutici), separated by 3 days wash-out intervals. Prothrombin Time (PT), Partial Thrombo plastin Time (PTT), Antithrombin III (ATIII), Heparin Cofactor II activity (HCII, measured by amidolytic method) were determined before each administration and after 30, 60, 120 and 240 minutes. Bleeding time (BT) and platelet count (PIC) were determined before and after 120 or 240 minutes respectively.No systemic or local adverse reactions were observed. Analysis of variance showed no significant modifications of PT, PTT, ATIII, BT and PIC following DS administrations nor significant differen ces between the three doses. A trend towards reduction was registered for HCII activity at 100 and 200 mg doses.Our results suggest that DS can be safely considered for further clinical investigation(*) F. Fernandez et al, Br J. Hematol, 64, 309, 1986
RESULTS OF THE MULTICENTRIC EVALUATION OF A NEW SYSTEM FOR PHOTOMETRIC DETERMINATION OF COAGULATION PARAMETERS
Authors: Dati F , Becker U , Keller J , Huber J , Schmitz-Huebner U , Ostermann H , Gressner A , Zimmermann R 
Published: August 2018

The classic coagulation analyses based on the clot formation present basic disadvantages which make a standardization of reagents difficult. The use of photometry for coagulation methods represents nowadays an important step towards test optimization.We have evaluated a new analytical system (ChromoTimeSystem, Behringwerke AG, Marburg/FRG) based on a special instrument and reagents for photometric tests for coagulation and fibrinolysis. The instrument is a microprocessor-controlled 4-channel-photometer operating at 37°C and connected to a microcomputer. Photometric methods for prothrombin time (PT: Chromoquick®) and activated partial thromboplastin time (aPTT: Partochrom®) have been developed using a new chromogenic substrate (Tos-Gly-Pro-Arg-5-amino-2-nitro-benzoic-acid-isopropy-lamide) specific for thrombin. These tests are based on the time necessary to attain a fixed increase of absorbance (0.1 A). Tests for thrombin time (TT), batroxobin time and fibrinogen rely on turbidimetric techniques. In the screening tests PT, aPTT and fibrinogen 25 μl sample (TT: 50 μl) and 250 μl reagent are used. Single coagulation factors are assayed by mixing an undiluted sample (10 μl) with the correspondent factor deficient plasma (50 μl) in connection with the chromogenic PT or aPTT reagent (500 μl). The evaluated specific chromogenic substrate methods are: antithrombin III, α2-antiplasmin and plasminogen.Tne characteristics of the ChromoTimeSystem are: fibrinogen-independent PT and PTT, small sample volumes (10-50 μl), no predilution or preincubation, PT standardization according to WHO recommendations, coefficients of variation between 1 and 4 %, good correlation between photometric and coagulometric tests, the reference values for photom. PTT being 90-120 sec.